Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Bolt Biotherapeutics Q3 2026 Results: Net Loss of $4.42M, Loss Narrows

Bolt Biotherapeutics reported a net loss of $19.5 million for the nine months ended September 30, 2026, a significant reduction from the $26.7 million loss in the prior year period. The company recently acquired Prana Therapies, Inc. to pivot its focus toward the INSPIRE platform for multispecific antibodies while completing Phase 1/2 trials for BDC-4182.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue0.02.2
Net income-4.4-7.1
EPS (diluted, $ a share)$-2.25$-3.72

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: BOLT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Bolt Biotherapeutics, Inc.: key numbers

Share price
$5.80Close, Nov 16
Market cap
$15.1M
Shares outstanding
2.61MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Bolt Biotherapeutics, Inc.

All →
4:12 PM ET 8-K
Financial Results

Bolt Biotherapeutics Financial Results

Bolt Biotherapeutics reported Q3 2026 financial results and provided a business update following its acquisition of Prana Therapies and a concurrent $120 million private placement. The company is shifting its primary focus to the INSPIRE-built pipeline, specifically the Phase 2 development of PRA-216 for inflammatory indications, with a cash runway extending into 2028.

“Completing the Prana acquisition marks an important transformation for Bolt. With a strong balance sheet, an advanced clinical program and a differentiated platform, we believe we are well positioned to execute against the important milestones ahead.”

Willie Quinn, President and Chief Executive Officer

“The transaction and financing provide us with the capital and public-company foundation to advance PRA-216 and the broader INSPIRE pipeline through what we believe will be an exciting and highly data-rich period ahead.”

Sheila Gujrathi, M.D., Chief Strategy Officer
2:57 PM ET Form 4
Insider Buying

Bolt Biotherapeutics Insider Coastlands Capital LP Buys $319K of Stock

Coastlands Capital LP bought 50,000 shares of Bolt Biotherapeutics, Inc. at $6.38 a share, worth $319K in total on Nov 9, 2026. Shares held after the trade: 462,416 (+12.1%).

Value
$319K
Shares
50,000
Price
$6.38
Holding change
+12.1%
Trade date
Nov 9, 2026
10:32 AM ET 8-K
M&A Deal

Bolt Biotherapeutics M&A Deal with Prana Therapies, Inc.

Bolt Biotherapeutics acquired Prana Therapies in a stock-for-stock reverse merger, issuing common and Series D preferred stock to Prana shareholders. Following the merger and a concurrent $120 million private placement, former Prana equityholders will own approximately 51.7% of the combined company. The transaction shifts Bolt's focus to Prana's INSPIRE platform and its lead bispecific antibody candidate, PRA-216, for inflammatory diseases.

Counterparty
Prana Therapies, Inc.
4:08 PM ET 8-K
Business Update

Bolt Biotherapeutics Business Update

Bolt Biotherapeutics entered into a second lease amendment for its Redwood City facilities, accelerating the lease expiration date to December 31, 2027, or earlier upon a strategic transaction. The company paid $1.0 million upfront and agreed to a $4.5 million termination payment upon a future corporate transaction, significantly reducing its ongoing rent and operating expense obligations.

Counterparty
HCP LS Redwood City LLC
Term
through Dec 2027
6:05 PM ET Form 4
Insider Selling

Bolt Biotherapeutics COO Grant Yonehiro Sells $38.5K of Stock

Grant Yonehiro, COO, sold 11,759 shares of Bolt Biotherapeutics, Inc. at $3.24 to $3.32 a share (average $3.27) in 2 transactions, worth $38.5K in total between Sep 17, 2026 and Sep 18, 2026. Shares held after the trade: 17,269 (-28.4%).

Value
$38.5K
Shares
11,759
Average price
$3.27
Role
COO
Holding change
-28.4%
Trade date
Sep 17, 2026 to Sep 18, 2026
6:05 PM ET Form 4
Insider Selling

Bolt Biotherapeutics Senior VP, Finance and PAO Sarah Nemec Sells $13.2K of Stock

Sarah Nemec, Senior VP, Finance and PAO, sold 4,077 shares of Bolt Biotherapeutics, Inc. at $3.24 a share, worth $13.2K in total on Sep 18, 2026. Shares held after the trade: 17,082 (-19.3%).

Value
$13.2K
Shares
4,077
Price
$3.24
Role
Senior VP, Finance and PAO
Holding change
-19.3%
Trade date
Sep 18, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.